Working with the media
Welcome to the European Medicines Agency’s online media centre. This page highlights information which is of specific interest to media professionals.
The page is kept updated with news, events and information for journalists with a professional interest in the development and availability of medicines in the European Union.
For more information, please contact the EMA press office.
Press briefing: Launch of PRIME - priority medicines
Watch the recording of our press briefing on 7 March to launch the PRIME scheme, which aims to bring promising innovative medicines to patients faster by optimising and supporting medicine development.
Human medicines highlights for 2015
EMA has released an overview of its key recommendations in 2015 on the authorisation of new medicines and the safety monitoring of authorised medicines. EMA recommended 93 medicines for marketing authorisation. This includes recommendations for 39 new active substances.
Search for all press releases, news items and other media materials.
All about medicines
Search for information on medicines and browse the European database of suspected adverse drug reaction reports.
Find out more about EMA's scientific committees and working parties
Funding, statistics and key operating information
News for media professionals
Six medicines, including one new antibacterial recommended for authorisation in the EU; antiseptic gel for newborns receives positive scientific opinion for use outside the EU ... Read more
Umbipro to help prevent umbilical cord infections ... Read more
Zavicefta is recommended for approval for patients with limited treatment options. ... Read more
Review finds no differences between products in risk of pneumonia ... Read more
- See all News for media professionals
Events of interest
Targeted consultation on the guideline for development of new medicinal products for the treatment of rheumatoid arthritis
In the frame of public consultation on the revision of the guideline on clinical investigation of medicinal products other than non-steroidal anti-inflammatory drugs (NSAIDs) for treatment of rheumatoid arthritis, the European Medicines Agency is hosting a meeting to supplement the ongoing debate. ... Read more
02/06/2016 - 03/06/2016
2016 annual workshop of the European network of paediatric research (Enpr-EMA) at the European Medicines Agency
The first day of the workshop is an open meeting to all stakeholders, including patient and parent organisations, network representatives, pharmaceutical industry staff responsible for paediatric studies and regulators. The main tocpics of the workshop this year will be the deliverables of the working groups and the implementation of the new Clinical Trial Regulation with a focus on ethics related issues. The second day is dedicated to members of Enpr-EMA and its coordinating group. ... Read more
04/02/2016 - 05/02/2016
Immunotherapy is becoming a fast growing area of new medicinal products in oncology. These new agents have brought important advances in patient care and have considerably changed the landscape of treatment options in melanoma and lung cancer patients. However, there are still many challenges on how to bring these agents through regulatory approval and into clinical practice. Appropriate patient population selection, new clinical trials designs, rational for the mechanism of action in different tumour types, innovative immunological-based products used in combination and assessing relative efficacy of these novel immunomodulating therapies are some of the key issues that we propose to address in a workshop organised with the Cancer Drug Development Forum (CDDF). The aim is to address these highly relevant issues and their impact on the regulatory environment. ... Read more
The European Medicines Agency (EMA) is hosting the second EMA-Industry Stakeholders Platform meeting on paediatric medicines. This meeting will serve as stage to discuss among other topics the experience, so far, with paediatric standard paediatric-investigation plans (PIPs), the pilot on early interaction on paediatric development and changes to the summary report and electronic submission. ... Read more
Medication errors are a major public health burden and error prevention is a shared responsibility between patients, healthcare professionals, regulators and pharmaceutical industry at all levels of healthcare delivery. This information day is an opportunity for pharmaceutical industry and regulatory agencies to exchange experience on the new European Union (EU) good practice guide on medication errors published by the EU regulatory network in 2015. The objective is to raise awareness of EU pharmacovigilance obligations for medication errors and to discuss operational aspects and good practice recommendations with regard to medication error reporting, evaluation and prevention, with insight into the current regulatory thinking on how to tackle medication errors within health care delivery systems for the benefit of patient safety. ... Read more
- See all Events of interest